Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles